Tuesday, 3 November 2026
M
Meridian Globe
Live briefing
Working collaboratively to fight scams in Asia Pacific— Google 官方博客Camarines Norte communities take charge of local climate fight— Rappler 菲律宾拉普勒St. Luke’s, NPC investigating data breach on mobile app— Rappler 菲律宾拉普勒Merz says next German president should be a woman— The Local Germany 德国本地Anthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei AsiaWorking collaboratively to fight scams in Asia Pacific— Google 官方博客Camarines Norte communities take charge of local climate fight— Rappler 菲律宾拉普勒St. Luke’s, NPC investigating data breach on mobile app— Rappler 菲律宾拉普勒Merz says next German president should be a woman— The Local Germany 德国本地Anthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei Asia

Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study

Source Nature 医学研究1d ago
Summary

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Health
Region
Global
Language
English
Item ID
health-7452731c

Comments 0 comments

No comments yet. Be the first.

Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study · Meridian Globe